Short steroid treatment may help manage teplizumab CRS without stopping therapy

Evidence Suggest

• Intravenous methylprednisolone and oral prednisone were used during the first CRS episode, and prednisone was used again during the second course.
• The patient completed both 12-day teplizumab courses without interruption after glucocorticoid treatment.
• Reported HbA1c values were 6.3% at 6 months, 6.4% at 15 months, 6.1% at 24 months, and 5.4% at 30 months.
• The authors reported ongoing low-dose basal insulin use and preserved mixed-meal C-peptide trends, which they interpreted as sustained partial remission.

Who this applies to

These findings apply most directly to adolescents or young people with new-onset type 1 diabetes receiving teplizumab who develop clinically significant cytokine release syndrome during treatment. Even then, the report reflects only one patient managed at a single center.

Keep in Mind

This paper mainly addresses adverse-event management, not a definitive test of teplizumab efficacy. The apparent benefit of glucocorticoids was limited to allowing treatment completion and symptom control in one patient. Because there was no formal comparison and many later outcomes reflect the broader effect of teplizumab itself, the case should be viewed as hypothesis-generating rather than practice-changing.

Between the Lines

• This was a single-patient case report.
• There was no direct control comparison for steroid use during CRS management.
• The patient was excluded from the parent trial analysis because glucocorticoids were prohibited.
• The report cannot show whether the same outcome would happen in other patients.